Membrane‐filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety

Membrane‐filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety

ABSTRACT Background While complement blockade with eculizumab is recommended as first‐line therapy of atypical hemolytic uremic syndrome (aHUS), plasma exchanges (PEX) remain the chief option for anti‐factor H (FH) antibody associated disease and when access to eculizumab is limited. Methods We revi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical apheresis 2019-10, Vol.34 (5), p.555-562
Hauptverfasser: Khandelwal, Priyanka, Thomas, Christy C., Rathi, Bhim Singh, Hari, Pankaj, Tiwari, Anand N., Sinha, Aditi, Bagga, Arvind
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Apheresis
Atypical Hemolytic Uremic Syndrome - complications
Atypical Hemolytic Uremic Syndrome - therapy
Catheters
central venous catheter
Child
Child, Preschool
clinical audit
complement factor H
Female
Filtration - methods
Humans
Infant
Male
Medical Audit
Membranes, Artificial
Plasma Exchange - adverse effects
Plasma Exchange - methods
plasmapheresis
Risk Factors
Tertiary Care Centers
Treatment Outcome
Urticaria
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Background While complement blockade with eculizumab is recommended as first‐line therapy of atypical hemolytic uremic syndrome (aHUS), plasma exchanges (PEX) remain the chief option for anti‐factor H (FH) antibody associated disease and when access to eculizumab is limited. Methods We reviewed adverse events (AEs) and adverse outcomes (eGFR
ISSN:0733-2459
1098-1101
DOI:10.1002/jca.21711